Technology
Health
Pharmaceutical

Ampio Pharmaceuticals

$0.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-3.51%) Today
-$0.02 (-3.51%) Today

Why Robinhood?

You can buy or sell AMPE and other stocks, options, ETFs, and crypto commission-free!

About

Ampio Pharmaceuticals, Inc, also called Ampio Pharmaceuticals, is a biopharmaceutical company, that engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. Read More The company was founded by David Bar-Or in April 2010 and is headquartered in Englewood, CO.

Employees
22
Headquarters
Englewood, Colorado
Founded
2010
Market Cap
63.24M
Price-Earnings Ratio
1.40
Dividend Yield
0.00
Average Volume
1.36M
High Today
$0.556
Low Today
$0.55
Open Price
$0.555
Volume
10.20K
52 Week High
$3.89
52 Week Low
$0.3511

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
US
North America

News

PR NewswireMar 6

Ampio Updates Regulatory Status for Ampion

ENGLEWOOD, Colo., March 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™. Food and Drug Administration (FDA) provided guidance that Ampio should complete an additional trial of Kellgren Lawrence Grade 4 (KL 4) osteoarthritis of the knee (OAK) patients with concurrent controls that would be carried out under a Special Protocol Assessment (SPA). Ampio presented the FDA with two different forms of concurrent controls the company was considerin...

276
Yahoo FinanceFeb 25

Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forwa

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Wolverine World Wide, Inc. (WWW), Viking Therapeutics, Inc. (VKTX), Ampio Pharmaceuticals, Inc. (AMPE), ArcelorMittal (MT), Delphi Technologies PLC (DLPH), and Unit Corporation (UNT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst ...

4,788
MarketBeatFeb 23

Stock Price, News, & Analysis for Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeabil...

121

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 21, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.